Resource Library
Protecting Your Valuable Brand in China
In recent years, the People’s Republic of China (PRC) has taken steps toward combatting counterfeiting, largely in response to grievances by foreign companies.
China’s Biopharma Rise Poses Increasing Risks to International Companies
For years, China has been welcoming foreign biopharma firms and investment in a bid to boost its burgeoning healthcare sector. In the first seven months of 2025, China attracted more than $4 billion of greenfield foreign direct investment (FDI), accounting for one-third of China’s FDI.
The Asia-Pacific is becoming a global hub for biotech and pharma innovation and drug discovery
Increasing aversion to risk in early-stage drug research and geopolitical tensions are driving U.S. and European companies to realign their R&D strategies. Asia Pacific is placing itself to become a significant global hub for biotech innovation.
Asian countries take big tariff hits, but the semiconductor and pharma industries remain exempt… for now
The sweeping trade tariffs imposed by President Trump have sent global stock markets into turmoil. The APAC region has been hit particularly hard. But, for now, the semiconductor and pharma industries have been granted exemptions. How long will that last?
The forthcoming U.S. BIOSECURE Act is already making an impact on the China business strategy of global pharmaceutical companies. What are the implications for your China risk exposure?
Biopharmaceutical companies worldwide have expressed their intentions to continue investing in China. However, the forthcoming U.S. BIOSECURE Act means that many are proactively reassessing their China business strategies. Pamir has been working with pharma
How are China and Russia advancing their shared agendas?
Download our recent analyst paper to understand the key implications of recent China-Russia diplomatic developments.
